Hanmi, Genexine, HanAll to unveil game-changing clinical results

Poziotinib, which was in-licensed from Hanmi, is a pipeline candidate for non-small cell lung cancer with exon 20 insertion … on the 12-month efficacy results of HyTropin as a bi-weekly therapy to treat lack of production of growth hormone in adults. (본문 전체 9/3/2018 4:55 PM)

Leave a Comment